Profile

Dmitriy Berenzon, M.D.Wake Forest Baptist Health

Doctor Rating

4.5 out of 5

115 Ratings
6 Comments
 

Dmitriy Berenzon, M.D.

Assistant Professor,

Clinical Interests

Acute and Chronic Leukemia, Hematologic Malignancies, Multiple Myeloma, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Additional Languages

Russian

Education & Training

  • M.D., I.P. Pavlov Leningrad-Russia, 1995
  • Residency, Internal Medicine, I.P. Pavlov Medical University, 1997
  • Residency, Internal Medicine, Methodist Hsp Of Brooklyn, 2007
  • Fellowship, Hematology And Oncology, Mount Sinai School of Medicine, 2010

Board Certifications

  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology

NPI Number

  • 1669631479
Dmitriy Berenzon, M.D.

Doctor Rating

4.5 out of 5

115 Ratings
6 Comments
 

Dmitriy Berenzon, M.D.

Assistant Professor, Hematology & Oncology

Research Interests

Plasmodium berghei; Malaria; CD8-Positive T-Lymphocytes; Hematopoietic Stem Cells; Immunologic Memory
More »

Contact Information

Academic: 336-716-1808 | Department: 336-716-4464

Recent Publications

CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway. Wu D, Guo X, Su J, Chen R, Berenzon D, Guthold M, Bonin K, Zhao W, Zhou X.. Biochim Biophys Acta. 2015;1853(2):338-347.

High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS.. Leuk Res. 2015;39(9):945-949.

Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R.. J Clin Oncol. 2015;33(33):3953-3960.

Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. J Clin Oncol. 2015;33(15 Suppl):7015.

CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway [abstract]. Wu D, Guo XY, Su J, Chen RY, Berenzon D, Bonin K, Guthold M, Zhao WL, Zhou XB.. Clin Cancer Res. 2015;21(17 Suppl):A09.

Phase 2 study of a novel controlled-release formulation of anagrelide (Gale-401) in subjects with myeloproliferative neoplasm (Mpn)-related thrombocytosis [abstract]. Verstovsek S, Saltzman M, Dakhil S, Bessudo A, Lyons R, Jawien W, Berenzon D, Mena R, Glidden P, Choy G, Laliberte R, Hamilton B,.. Haematologica. 2015;100(Suppl 1):263.

Final results of anagrelide controlled-release (GALE-401) safety, efficacy and pharmacokinetics in subjects with myeloproliferative neoplasms (MPN)-related thrombocytosis [abstract]. Troung PV, Saltzman M, Bessudo A, Jawien W, Lyons RM, Berenzon D, Mena R, Wingate-Pearse N, Barriere O, Beeson HE, Glidden PF, Choy GS, Verstovsek S.. Blood. 2015;126(23):4074.

The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL.. Blood. 2015;126(23):2556.

Feasibility of a symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) [abstract]. Klepin HD, Tooze J, Pardee T, Ellis LR, Berenzon D, Howard D, Demark-Wahnefried W, Mihalko S, Rejeski WJ, Powell BL, Kritchevsky S.. Blood. 2015;126(23):2102.

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T.. Ann Hematol. 2014;93(1):47-55.

The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL.. Blood. 2014;124(21):3744.

Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. Chaurasia P, Berenzon D, Hoffman R.. Blood. 2011;117(17):4632-4641.

Chromatin modifying agents promote the ex vivo production of functional human erythroid progenitor cells [abstract]. Chaurasin P, Berenzon D, Hoffman R.. Blood. 2010;116(21):154.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Assistant Professor, Hematology & Oncology

Clinical Interests

Acute and Chronic Leukemia, Hematologic Malignancies, Multiple Myeloma, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis
Dmitriy Berenzon, M.D.

Dmitriy Berenzon, M.D.

Assistant Professor, Hematology & Oncology

Doctor Rating

4.5 out of 5

Dmitriy Berenzon, M.D.115 Ratings
6 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.6
CP efforts to include in decisions
4.6
CP explanations of prob/condition
4.6
CP spoke using clear language
4.6
Friendliness/courtesy of CP
4.7
Likelihood of recommending CP
4.6
Patients' confidence in CP
4.7
Time CP spent with patient
4.5
Wait time at clinic
3.6



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

7/23/2016

Providers immediate follow-up on medication was outstanding - best ever!

6/8/2016

He has helped tremendously with my blood disorder when other Dr. could not find the right combinations that I needed

4/28/2016

I feel blessed to have *Dr. Berenzon and his team as my cancer care provider.

3/28/2016

Always tries to help me like my family.

2/23/2016

I consider *Dr. Berenzon a top flight Oncologist.

12/31/2015

Bad

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.